Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Granufink is a line of herbal medicinal products primarily used for the treatment of lower urinary tract symptoms (LUTS) and bladder complaints. The most common formulations include Granufink Prosta forte 500 mg and Granufink Prosta plus Sabal. These products are based on plant-derived active ingredients such as thick extract from pumpkin seeds (Cucurbita pepo), sometimes combined with saw palmetto fruit dry extract (Serenoa repens) or other botanicals like hop cones and fragrant sumac bark in specific variants. The mechanism of action is not fully elucidated but is believed to involve anti-inflammatory effects, modulation of bladder function, and support for prostate health through phytosterols and fatty acids present in the extracts. Granufink products are marketed as traditional herbal medicines registered based on long-standing use rather than clinical trial data equivalent to pharmaceuticals. They are indicated for mild to moderate urinary symptoms associated with benign prostatic hyperplasia in men or overactive bladder/bladder weakness in women[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on granufink.